Ursodeoxycholic acid and COVID-19 outcomes: a cohort study and data synthesis of state-of-art evidence.
Expert Rev Anti Infect Ther
; : 1-12, 2024 Jul 09.
Article
in En
| MEDLINE
| ID: mdl-38975666
ABSTRACT
BACKGROUND:
The potential of ursodeoxycholic acid (UDCA) in inhibiting angiotensin-converting enzyme 2 was demonstrated. However, conflicting evidence emerged regarding the association between UDCA and COVID-19 outcomes, prompting the need for a comprehensive investigation. RESEARCH DESIGN ANDMETHODS:
Patients diagnosed with COVID-19 infection were retrospectively analyzed and divided into two groups the UDCA-treated group and the control group. Kaplan-Meier recovery analysis and Cox proportional hazards models were used to evaluate the recovery time and hazard ratios. Additionally, study-level pooled analyses for multiple clinical outcomes were performed.RESULTS:
In the 115-patient cohort, UDCA treatment was significantly associated with a reduced recovery time. The subgroup analysis suggests that the 300 mg subgroup had a significant (adjusted hazard ratio 1.63 [95% CI, 1.01 to 2.60]) benefit with a shorter duration of fever. The results of pooled analyses also show that UDCA treatment can significantly reduce the incidence of severe/critical diseases in COVID-19 (adjusted odds ratio 0.68 [95% CI, 0.50 to 0.94]).CONCLUSIONS:
UDCA treatment notably improves the recovery time following an Omicron strain infection without observed safety concerns. These promising results advocate for UDCA as a viable treatment for COVID-19, paving the way for further large-scale and prospective research to explore the full potential of UDCA.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Expert Rev Anti Infect Ther
Year:
2024
Document type:
Article